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Investigating the causal effect of 
smoking on hay fever and asthma: 
a Mendelian randomization meta-
analysis in the CARTA consortium
Tea Skaaby  1, Amy E. Taylor2,3, Rikke K. Jacobsen1, Lavinia Paternoster2, Betina H. 
Thuesen1, Tarunveer S. Ahluwalia4,5,6, Sofus C. Larsen7, Ang Zhou8, Andrew Wong  9, Maiken 
E. Gabrielsen10,11, Johan H. Bjørngaard12,13, Claudia Flexeder14, Satu Männistö15, Rebecca 
Hardy9, Diana Kuh9, Sarah J. Barry16, Line Tang Møllehave1, Charlotte Cerqueira1, Nele 
Friedrich1,17, Tobias N. Bonten18,19, Raymond Noordam20, Dennis O. Mook-Kanamori19,21,22, 
Christian Taube23, Leon E. Jessen  4, Alex McConnachie16, Naveed Sattar24, Mark N. Upton25, 
Charles McSharry26, Klaus Bønnelykke4, Hans Bisgaard4, Holger Schulz14,27, Konstantin 
Strauch28,29, Thomas Meitinger30,31,32, Annette Peters32,33, Harald Grallert33,34,35, Ellen A. 
Nohr36, Mika Kivimaki  37, Meena Kumari38, Uwe Völker39, Matthias Nauck17, Henry Völzke40, 
Chris Power41, Elina Hyppönen8,41,42, Torben Hansen5, Torben Jørgensen1,43,44, Oluf Pedersen5, 
Veikko Salomaa47, Niels Grarup  5, Arnulf Langhammer45, Pål R. Romundstad13, Frank 
Skorpen11, Jaakko Kaprio  46,47,48, Marcus R Munafò  2,3 & Allan Linneberg  1,49,50
Observational studies on smoking and risk of hay fever and asthma have shown inconsistent results. 
However, observational studies may be biased by confounding and reverse causation. Mendelian 
randomization uses genetic variants as markers of exposures to examine causal effects. We examined 
the causal effect of smoking on hay fever and asthma by using the smoking-associated single nucleotide 
polymorphism (SNP) rs16969968/rs1051730. We included 231,020 participants from 22 population-
based studies. Observational analyses showed that current vs never smokers had lower risk of hay fever 
(odds ratio (OR) = 0·68, 95% confidence interval (CI): 0·61, 0·76; P < 0·001) and allergic sensitization 
(OR = 0·74, 95% CI: 0·64, 0·86; P < 0·001), but similar asthma risk (OR = 1·00, 95% CI: 0·91, 1·09; 
P = 0·967). Mendelian randomization analyses in current smokers showed a slightly lower risk of hay 
fever (OR = 0·958, 95% CI: 0·920, 0·998; P = 0·041), a lower risk of allergic sensitization (OR = 0·92, 
95% CI: 0·84, 1·02; P = 0·117), but higher risk of asthma (OR = 1·06, 95% CI: 1·01, 1·11; P = 0·020) per 
smoking-increasing allele. Our results suggest that smoking may be causally related to a higher risk 
of asthma and a slightly lower risk of hay fever. However, the adverse events associated with smoking 
limit its clinical significance.
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Smoking is one of the most common modifiable risk factors for disease in adults. It has been suggested that smok-
ing affects the risk of allergic respiratory disease and asthma1–3. Some studies have shown a positive association 
between smoking and asthma4–6, while others have found no or even an inverse association7–9, The effect of smok-
ing on hay fever (allergic rhinitis) is also not clearly established although a systematic review and meta-analysis 
from 2014 of 34 observational studies (concerning active smoking and hay fever) found no association1. Allergic 
sensitization to inhalant allergens can be assessed by skin prick testing and/or measurements of serum specific 
IgE. These are generally accepted objective markers of allergic respiratory disease that can be used both in clinical 
assessment and epidemiological studies. Some but not all studies have observed a lower prevalence of allergic sen-
sitization among current smokers compared to never smokers1, and we recently confirmed this in a meta-analysis 
of more than 20,000 participants from seven population-based studies10. However, inferring causal relationships 
between smoking and allergic respiratory disease from observational data is difficult due to confounding and 
reverse causation.
Mendelian randomization is a method for examining possible causal associations by using genetic variants 
with well-known effects on exposure patterns as proxies for exposure11. Mendelian randomization is based on 
the assumption of random allocation of alleles from parent to child. It takes advantage of the fact that the genetic 
variants will not be associated with the confounding factors and reverse causality inherent in conventional obser-
vational studies.
The rs16969968 single nucleotide polymorphism (SNP) is associated with smoking heaviness within smokers. 
The risk allele, here the minor allele, is associated with an average increase in smoking amount of one cigarette 
per day in smokers12–14. The rs16969968 SNP is in perfect linkage disequilibrium with rs1051730, and they are 
used interchangeably. These genetic proxies for smoking, unlike smoking heaviness itself, are not associated with 
confounding factors that may distort associations with health outcomes, for example, socioeconomic status and 
education level15. To test the causal nature of the associations between smoking and hay fever, asthma, and allergic 
sensitization, we performed a Mendelian randomization meta-analysis combining data from 22 studies in the 
Causal Analysis Research in Tobacco and Alcohol (CARTA) consortium and the UK Biobank.
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Methods
Study populations. The study was performed as a meta-analysis within the CARTA consortium (http://
www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta). We used data on 231,020 partici-
pants of self-reported European ancestry and aged ≥16 years from 22 studies from the CARTA consortium: The 
British 1958 Birth Cohort (1958BC), the Avon Longitudinal Study of Parents and Children (ALSPAC) Mothers, 
ALSPAC Children, COPSAC2000, the Danish Monitoring of trends and determinants in Cardiovascular 
Diseases (MONICA) study (the Dan-Monica10 study), the English Longitudinal Study of Ageing (ELSA), the 
National FINRISK Study (FINRISK), Genomics of Overweight in Young Adults (GOYA) Females, GOYA Males, 
Health2006, Health2008, the second wave of the Nord-Trøndelag health study (HUNT2), Inter99, the Cooperative 
Health Research in the Region of Augsburg (KORA) study, the Middle-aged Span-of-Life (MIDSPAN) Family 
Study, the MRC National Survey of Health and Development (NSHD), the 1936 Cohort, the UK Biobank, the 
Netherlands Epidemiology of Obesity (NEO) study, Whitehall II, the Study of Health in Pomerania (SHIP) and 
SHIP-TREND (See online supplementary material).
The British 1958 Birth Cohort was approved by the South-East Multi-Centre Research Ethics Committee 
and the joint UCL/UCLH Committees on the Ethics of Human Research. The ALSPAC Mothers and Children 
were approved by the ALSPAC Ethics and Law Committee and the Research Ethics Committee. COPSAC2000 
was approved by Copenhagen Ethics Committee and the Danish Data Protection Agency. The Dan-Monica10 
study, the Health2006 Study, the Health2008 Study, the Inter99 Study, and the 1936 Cohort were approved by the 
Ethics Committee of Copenhagen County and the Danish Data Protection Agency. ELSA was approved by the 
National Research Ethics Service. FINRISK was approved by the Coordinating Ethics Committee for the Uusimaa 
Hospital District. GOYA Females was approved by the Ethical Committee of Copenhagen and the Danish Data 
Protection Board. GOYA Males was approved by the Ethics Committee for Copenhagen and the Danish Data 
Protection Board. HUNT2 was approved by the Regional Committee for Medical Research Ethics. KORA was 
approved by the Ethics Committee of the Bavarian Medical Association. MIDSPAN Family Study was approved 
by the Argyll and Clyde Health Board Local Research Ethics Committee. NSHD was approved by the Central 
Manchester Research Ethics Committee. UK Biobank was approved by the Ethics and Governance Council. The 
NEO study was approved by the Medical Ethical Committee of the Leiden University Medical Center. Whitehall 
II was approved by the University College London Medical School committee on the ethics of human research. 
SHIP and SHIP-TREND were approved by the Ethics Committee of the University of Greifswald. All participants 
gave their informed consent, and all methods were carried out in accordance with relevant guidelines and regu-
lations (more information in the Supplementary).
Genotype. Each participant was genotyped for either rs16969968 or rs1051730. Both are located in the 
CHRNA5-A3-B4 nicotinic receptor subunit gene cluster and in perfect linkage disequilibrium in Europeans 
(R2 = 1·00 in HapMap 3, http://hapmap.ncbi.nlm.nih.gov/). Description of the method for genotyping within 
each study is provided in the online supplementary material.
Measures of hay fever, asthma, and allergic sensitization. Data on hay fever and asthma were based on 
self-report. Our first choice was lifetime/ever diagnoses, but alternatively we used a diagnosis in the past 12 months 
or longer. Allergic sensitization was defined as serum specific IgE positivity to at least one of the tested inhalant aller-
gens. The study-specific measures of hay fever, asthma and allergic sensitization are provided in Table S3.
Smoking status. Smoking status classified as never, former, current or ever (former and current smokers) 
cigarette smokers was assessed at the same time as the outcome if available. Smoking heaviness was measured 
as cigarettes smoked per day or recoded to the midpoint of the category. More information is provided in the 
online supplemental material and the protocol: http://www.bris.ac.uk/expsych/research/brain/targ/research/
collaborations/carta/.
Statistical analyses. Analyses were conducted within each contributing study according to the same 
pre-specified analysis protocol: http://www.bris.ac.uk/expsych/research/brain/targ/research/collaborations/carta/.
We restricted the analyses to participants with data on disease outcomes (at least one of the three outcomes), 
smoking status and rs16969968/rs1051730 genotype. Sex- and age-adjusted associations of smoking status (never 
[reference group], former, current, ever) and smoking heaviness with dichotomous measures of hay fever, asthma, 
and allergic sensitization were assessed using logistic regression. The smoking heaviness analyses were restricted 
to current smokers and to studies with continuous measures of cigarettes per day. Hence, odds ratios (ORs) rep-
resent differences in odds of the outcome measure per additional cigarette consumed per day.
The genotype frequencies were tested for deviation from Hardy-Weinberg equilibrium (HWE) using a χ2 
exact test within each study. Mendelian randomization analyses of the association between rs16969968/rs1051730 
and dichotomous measures of hay fever, asthma and allergic sensitization were performed using logistic regres-
sion, both unadjusted and adjusted for age and sex. We stratified the analyses by smoking status (never, former, 
current and ever), because the variant only influences smoking heaviness in smokers16. We assumed an addi-
tive genetic model which means that ORs represent the ratio in odds of the outcome per additional copy of the 
smoking-increasing allele.
The results were meta-analyzed in Stata, version 12.1 (StataCorp LP, College Station, Texas, USA) using the 
‘metan’ command where heterogeneity was evaluated by the I-square test17, 18. If there was evidence of heterogene-
ity between studies (I2 > 50%), we performed both fixed and random effect analyses (Figs 1–3 and Supplementary 
Figures S1–S24). The random effects model was based on the method of DerSimonian & Laird and the estimate 
of heterogeneity from the Mantel-Haenszel model18.
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The results from meta-analyses are summarized in Figs 1–3. The detailed meta-analyses showing age- and 
sex-adjusted study-specific estimates are shown in Supplementary Figures S1–S8 (the crude associations are 
shown in S9–S16). We also performed analyses with and without UK Biobank (Figures S17–S20), and without 
ALSPAC Mothers and ALSPAC Children (Figures S21–S22 and Figures S23–S24, respectively).
Role of the funding source. The study sponsors were not involved in study design; in the collection, analy-
sis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. 
The corresponding author had full access to all the data in the study and had final responsibility for the decision 
to submit for publication.
Results
Descriptive statistics. In total, we had data on 231,020 participants, including 115,839 never smokers, 
70,858 former smokers and 44,323 current smokers. Overall, 45·5% of the combined study population were 
males (Nmales = 105,203). The median age within the contributing studies ranged from 18 to 64 years. Descriptive 
statistics for each of the study populations are found in the Supplemental Table S1. Minor allele frequency for 
rs16969968/rs1051730 ranged between 0·32 and 0·37 (Supplemental Table S2). The genotype distribution did not 
deviate from Hardy Weinberg Equilibrium in any of the studies (P-values all ≥ 0·05) (Supplemental Table S2). 
For the Mendelian randomization analyses, the number of participants were for hay fever: N = 208,365, asthma: 
N = 231,013, and allergic sensitization: N = 17,623. The percentage with hay fever (Nhayfever = 41,170), asthma 
(Nasthma = 24,199) and allergic sensitization (Nallergic sensitization = 4,573) varied between 8·0–54·0%, 3·7–61·7%, and 
13·8–50·3%, respectively (Table S1).
Observational analyses. Figures 1 and 2 show the estimates from meta-analyses of the age- and 
sex-adjusted associations of smoking status and smoking heaviness with hay fever, asthma and allergic sen-
sitization, respectively. For current smokers (but not former smokers) compared to never smokers, we found 
Figure 1. Age- and sex-adjusted associations of smoking status with hay fever, asthma and allergic sensitization 
using random effect meta-analysis.
Figure 2. Age- and sex-adjusted associations of smoking heaviness with hay fever, asthma and allergic 
sensitization using fixed effect meta-analysis.
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a lower risk of hay fever (OR = 0·68, 95% CI: 0·61, 0·76; P < 0·001) and, accordingly, we found an inverse 
dose-response relationship between smoking heaviness and hay fever (OR = 0·99 per cigarette per day, 95% CI: 
0·98, 0·99; P < 0·001) (Fig. 2). We found a higher risk of asthma in former smokers compared with never smokers 
(OR = 1·11, 95% CI: 1·01, 1·21; P = 0·022), but not for current smokers (OR = 1·00, 95% CI: 0·91, 1·09; P = 0·967) 
(Fig. 1). However, there was a positive dose-response relationship between smoking heaviness and asthma in 
current smokers (OR = 1·01, 95% CI: 1·01, 1·02; P < 0·001) (Fig. 2). For allergic sensitization, we found a lower 
risk in former (OR = 0·81, 95% CI: 0·73, 0·90; P < 0·001) and current smokers (OR = 0·74, 95% CI: 0·64, 0·86; 
P < 0·001) compared with never smokers (Fig. 1), but no association with smoking heaviness (OR = 1·00, 95% CI: 
0·99, 1·01; P = 0·578) (Fig. 2).
The heterogeneity in the analyses of smoking status was considerable (>80%, Fig. 1), and the estimates pre-
sented are therefore based on random effect meta-analysis. The smoking heaviness analyses showed little evidence 
of heterogeneity and were analysed with fixed effect meta-analysis (Fig. 2).
Mendelian randomization analyses. Our results confirmed that the smoking-increasing allele of 
rs1051730/rs16969968 is associated with an increase in smoking heaviness of approximately 1 cigarette/day in 
current smokers (Figure S8). Figure 3 shows the Mendelian randomization analyses of the age- and sex-adjusted 
associations of rs1051730/rs16969968 and hay fever, asthma, and allergic sensitization. We found some evidence 
that the smoking-increasing allele was associated with lower odds of hay fever in current smokers (OR = 0·958, 
95% CI: 0·920, 0·998; P = 0·041). There were no associations of genotype with disease in never (OR = 1·00, 95% 
CI: 0·98, 1·02; P = 0·857) or former smokers (OR = 1·00, 95% CI: 0·97, 1·03; P = 0·835) (Fig. 3). In line with this, 
the smoking-increasing allele tended to associate with lower risk of allergic sensitization in current smokers 
(OR = 0·92, 95% CI: 0·84, 1·02; P = 0·117). In contrast, the smoking-increasing allele was associated with a higher 
risk of asthma in current smokers (OR = 1·06, 95% CI: 1·01, 1·11; P = 0·020) (Fig. 3). The same tendency was 
found in the never smokers (OR = 1·03, 95% CI: 1·00, 1·06; P = 0·080).
The analyses of smoking heaviness according to genotype showed little heterogeneity between studies and 
were analysed with fixed effect meta-analysis (Figure S8). Except for allergic sensitization showing moderate 
heterogeneity, the heterogeneity in the analyses of rs1051730/rs16969968 in relation to disease outcomes was 
low (Fig. 3). Therefore, the analyses for hay fever/asthma and allergic sensitization were performed with fixed 
and random effect meta-analysis, respectively. In general, the unadjusted Mendelian randomization analyses 
yielded similar results which were expected since the genetic variant should be independent of confounding 
factors (Figures S13–S15).
Figure 3. Mendelian randomization analysis of the age- and sex-adjusted associations of rs1051730 or 
rs16969968 and hay fever (N = 208,365), asthma (N = 231,013) and allergic sensitization (N = 17,623) using 
fixed effect meta-analysis, except for allergic sensitization where we used random effect meta-analysis. Please 
note that the sum of former and current smokers is not equal to the number of ever smokers since GOYA 
Females are included in current smokers but not in ever smokers.
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Supplementary analyses. Since UK Biobank data represented the largest sample and because approxi-
mately one third of the UK Biobank sample with genetic data was selected on smoking status, and lung function 
(including criteria related to asthma), analyses without UK Biobank data (Figures S17–S18) and of UK Biobank 
samples alone (Figures S19–S20) were performed19. ALSPAC Mothers and ALSPAC Children were analyzed as 
separate samples in the main analyses although the mothers and children were related. However, the results from 
analyses excluding ALSPAC Mothers and ALSPAC Children, respectively, showed similar results (Figures S21–
S22 and figures S23–S24). In analyses of UK Biobank data only, we adjusted the observational analysis of the 
association of smoking status with hay fever and asthma in addition for total household income. This additional 
adjustment for household income changed the odds ratios for current and former smokers compared to never 
smokers less than 5% (0.9–4.9%). In addition, the smoking associated SNP was not associated with total house-
hold income in the UK Biobank Study (Chi2-test: p = 0.99).
Discussion
A meta-analysis of 22 population-based studies was performed including 231,020 participants of European ances-
try using both observational and Mendelian randomization analyses. In the latter, we found a slightly lower risk 
of hay fever and higher risk of asthma in current smokers with genetically determined heavier smoking. However, 
these associations were not evident among ever smokers. We also observed a tendency toward a lower risk of 
allergic sensitization associated with smoking. However, the power to show an effect was much lower for allergic 
sensitization, and there may still be a small to moderate effect of smoking on the risk of allergic sensitization. In 
general, our MR findings supported our observational analyses.
The observed inverse associations of smoking and hay fever among current smokers in both observational 
and Mendelian randomization analyses are somewhat in contrast with a meta-analysis by Saulyte et al. who found 
no association between smoking and allergic rhinitis1. The inverse association between smoking and allergic res-
piratory disease may reflect an immunosuppressive effect of smoking but could also (at least in the observational 
analysis) be due to reverse causality20, 21. It is possible that allergic smokers are more likely not to smoke or to quit 
smoking, sometimes referred to as the healthy smoker effect, i.e. the observed inverse association of smoking and 
hay fever may not be causal. Our results from the Mendelian randomization approach seem to support the results 
of the traditional observational approach in that smoking increases risk of asthma but decreases risk of hay fever. 
As regards observational analyses, they show that ex-smokers have lower risk of atopy and it is also important to 
note that longitudinal analyses have shown lower incidence of atopy in current smokers20, findings that are diffi-
cult to reconcile with the idea that smokers who develop an allergy tend to quit smoking.
The observed positive association between smoking and asthma among current smokers in our Mendelian 
randomization analysis and observational analysis of smoking heaviness is in line with a study by Coogan et al. 
who found that active smoking increased the incidence of adult-onset asthma and evidence for a dose-response 
relationship in a study of more than 45,000 African-American women with a 16 year follow-up6. Other stud-
ies have found similar associations5. However, some studies have found a lack of or an inverse association7–9. 
Possible mechanisms include a smoking-induced increased Th2 response and airway hyper-reactivity22. Studies 
in humans and animals have reported several effects of tobacco smoke on the airways (e.g., increased perme-
ability, inflammation, and changes in gene expression)23, 24. The inhaled smoke comes into direct contact with 
the airway epithelium. Beyond being a barrier, the epithelium is important in immune regulation: it influences 
inflammatory cell recruitment through cytokine and chemokine secretion and influences remodeling of the tis-
sue through growth factors25. In addition, increased exposure to passive smoking among children carrying and 
“sharing” the smoking-increasing allele with their parents may affect early immune programming and the risk of 
asthma in the offspring26, 27. This may also potentially explain the borderline (positive) association in never smok-
ers. In addition, the borderline effect in never smokers may also be due to, for example, former smokers being 
falsely classified as never smokers, and differential underreporting of smoking habits. However, the three studies 
that have potentially included both never and ex-smokers in the never smokers category (COPSAC2000, GOYA 
Females, and NSHD) do not seem to explain the borderline association among never smokers. Smokers in general 
tend to underreport their smoking habits, and smokers with asthma may be even more likely to underreport their 
smoking compared to smokers without asthma and smokers with diseases that are not believed to be related to 
smoking. This will tend to falsely increase the effect in never smokers but only if the current smokers with asthma 
underreporting smoking are unequally distributed regarding the SNP; otherwise it will not make a difference. 
However, it will tend to underestimate the effect in current smokers.
The observed tendency toward a lower risk of allergic sensitization associated with smoking is somewhat 
comparable to the observational association as well as to several previous studies20, 28, 29. Recently, we found a 
lower prevalence of allergic sensitization among current smokers versus never smokers in 20,048 participants 
from seven Danish studies10 that may reflect an immunosuppressive effect of smoking20. Compared with hay fever 
and asthma, we had substantially less data on allergic sensitization and thus may lack power to show a moderate 
or weak effect of smoking on allergic sensitization, so caution must be taken in ruling out an effect on allergic 
sensitization.
The reasons why the observed effects of the smoking-increasing allele were mainly seen in current smokers 
and not in former smokers are not clear. It is plausible that an effect of any given exposure decreases with increas-
ing time following ceased exposure. We did not have data to investigate that hypothesis. Assuming that the effects 
of smoking on hay fever and asthma go through immunological pathways it may also be hypothesized that the 
effects decrease relatively fast following smoking cessation, which could explain why the smoking increasing allele 
does not have any effects among former smokers.
The major strengths of this study are the large sample size and the inclusion of different populations. We used 
objective markers of allergic sensitization (i.e., serum specific IgE positivity against inhalant allergens) that may 
be more reliable than self-reported diagnoses and symptoms. We performed a number of supplementary analyses 
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with the results largely unchanged. Using a genetic marker of exposure should support stronger causal inference 
because genetic variants should not be associated with the usual confounding factors, they will indicate long-term 
levels of exposure, and are not affected by the onset of disease and thus protected from reverse causation. The 
smoking-associated rs16969968/rs1051730 genotype is strongly and consistently associated with smoking heav-
iness among smokers, has shown to be a solid instrument for smoking, and has shown the expected causal asso-
ciations with increased all-cause mortality, decreased lung function, and BMI30–35. However, using more than 
a single SNP, e.g., SNPs reflecting different pathways to the exposure, may reduce the risk of pleiotropy, but we 
know of no other smoking-associated SNP with strength and consistency similar to the rs16969968/rs1051730 
genotype, so this might introduce weak instrument bias36.
A limitation of the current study is the use of self-reported hay fever and asthma rather than clinical 
doctor-verified diagnoses or objective markers and that different questionnaires were used across studies. Further, 
we did not have information about the disease severity. The use of “ever” phenotypes is potentially problematic, 
since the outcome could precede smoking behavior, and it does not allow us to see whether smoking worsens 
symptoms of allergy/asthma. The prevalence of outcomes varied between populations possibly due to differences 
between populations in age, socioeconomic factors, and year of examination. This could influence our results and 
induce heterogeneity, which we also observed in the observational analyses. However, the heterogeneity of the 
MR analyses was relatively low suggesting that the variation in outcome prevalence did not introduce substantial 
heterogeneity in those analyses. Lacking a longitudinal design, we were unable to distinguish between the inci-
dence, persistence or recurrence of asthma. Regarding asthma in particular, it is difficult to distinguish between 
chronic obstructive pulmonary disease (COPD) and asthma using self-report, and it is possible that some of those 
who reported to have asthma may have had COPD. In addition, some may suffer from the overlap syndrome of 
asthma and COPD37. Misclassification of participants with COPD as having asthma would tend to inflate the 
observed association between smoking and asthma. The studies including only persons younger than 50 years 
may represent a more precise asthma group. However, all studies with participants younger than 50 years (1958 
BC, ALSPAC Children, and GOYA Females) and the studies where participants are below 52 years (ALSPAC 
Mothers, and COPSAC2000) have odds ratios larger than one. Given the size of the current study, it may be 
reasonable to conclude that smoking is associated with a higher risk of asthma, in spite of some potential mis-
classification. Collider bias of Mendelian randomization analyses may arise from stratification if the instrument 
is predictive of the stratification parameter. However, since our instrument rs16969968/rs1051730 is associated 
with smoking heaviness in smokers rather than with smoking initiation, we consider this to be a minor risk. The 
reason for not performing a formal instrumental variable analysis is the imprecision in self-reported cigarettes/
day as a measure of exposure that may lead to severely biased estimates38. However, this does not affect the causal 
insights of the Mendelian randomization approach.
The effects of smoking on the immune system in general are not clear but accumulating evidence suggests that 
smoking compromises the immune response39. Of the more than 45,000 chemicals contained in cigarette smoke, 
tar and nicotine are believed to be the most important regarding smoking’s effect on the immune system. Studies 
suggest that they suppress the immune response and increase the susceptibility to infections in various ways. 
Nicotine has been found to negatively affect antigen mediated signal transduction in lymphocytes and induces a 
state of T cell anergy39. Chronic exposure to tobacco smoke has been found to decrease levels of surfactant in the 
lungs, impair the ciliary epithelium, and reduce phagocytic function of macrophages to clear inflammation and 
debris from the lungs. In animal studies, chronic exposure to cigarette smoke or nicotine inhibits the responsive-
ness of T cells with decreased antibody response. Smoking has also been found to alter the function of neutrophils 
and the immune response of the lymphocytes39.
Mendelian randomization is a powerful tool for strengthening causal inference in epidemiological studies. 
It is becoming increasingly popular as a supplement to observational studies and an alternative to randomized 
controlled trials (RCTs), and it is clarifying a number of previously misconceived associations40, 41. Compared to 
RCTs, Mendelian randomization studies require no random treatment allocation, are more feasible, and often 
have fewer ethical concerns. MR studies can like other observational studies be performed in a representative 
sample in contrary to RCTs that are frequently carried out in otherwise healthy adults. However, potential viola-
tors of the inherent Mendelian randomization assumptions include canalization (i.e., developmental changes try-
ing to compensate for the genetic variation), linkage disequilibrium between the SNP and other causal variants, 
and biological pleiotropy where the genetic variant has diverse biological functions.
This large Mendelian randomization meta-analysis suggests that smoking may be causally related to a higher 
risk of asthma, and asthma should maybe be added to the long list of smoking-induced diseases. Thus, our results 
strengthen advice against smoking to reduce incidence and burden of chronic diseases. On the other hand, our 
results are somewhat supportive of a minor preventive effect of smoking on hay fever. However, this hypothesis 
needs confirmation and further investigation of the possible pathogenic pathways. The high frequency of adverse 
events associated with smoking, to a great extent limits its clinical significance.
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